Interestingly, the IL-6 receptor antagonists (e.g., tocilizumab) that are used as an adjunctive anti-inflammatory treatment for patients with severe COVID-19 recalcitrant to glucocorticoids may reduce AAT expression (since IL-6 induces AAT) [91]. The gene discussed is SERPINA1; the disease is COVID-19.